Background: High dose (>1.5 gm/m 2) Ara-C (HiDAC) given during induction is effective and well-tolerated in patients with AML <60. We report safety and efficacy of HiDAC in AML patients ≥60. Results: ...

Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper ...

Acute myeloid leukemia (AML) is a progressive type of cancer that affects your bone marrow and blood cells. Early detection and treatment are important to help increase the chances of survival from ...

– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines ...